Physician profile
Uma Gunnala
NPI 1881770220
$3,332.25
in general payments reported to CMS, 2019-2025
22 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $471 · 2021: $541 · 2022: $552 · 2023: $408 · 2024: $492 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,442.23 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $320.07 | 2019-2024 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.34 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $244.20 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $196.44 | 2022-2024 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $116.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $106.47 | 2021 | |
| Pfizer INC. | $104.09 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $88.74 | 2019-2021 | |
| Amarin Pharma, INC. | $65.79 | 2019-2020 | |
| Abbott Laboratories | $63.76 | 2021-2022 | |
| Shield Therapeutics INC | $54.89 | 2022-2024 | |
| Edwards Lifesciences Corporation | $39.90 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.46 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $31.63 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28.98 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $22.91 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.87 | 2022 | |
| Optos, INC. | $16.76 | 2022 | |
| Glaxosmithkline, LLC. | $15.40 | 2025 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $13.49 | 2025 | Nexletol |
| Sanofi Pasteur INC. | $13.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uma Gunnala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.